Protox, a biopharmaceutical affiliate of Synergy Partners Group, announced on the 3rd that it will successfully end phase 1 clinical trial of its own botulinum toxin type A, “Protoxin” and begin phase 2 clinical trial.

Protox has secured stability in the phase 1 clinical trial conducted after approval of the clinical trial plan last year, and in the phase 2 clinical trial, it plans to verify and evaluate the effectiveness of improving moderate or severe wrinkles of Protoxin.

Protoxin was developed through its own research and development at Protox, and as a result of analyzing the gene sequence by commissioning its strain to a genetic analysis agency, it was 99.99% consistent with ATCC3502 species registered with the National Center for Biological Information (NCBI).

The Protoxin Bio Production Plant began construction in May 2017 in the Hyangnam Pharmaceutical Complex in Hwaseong-si, Gyeonggi-do, and was completed in more than two years.The plant, which has a total project cost of about 32 billion won, has a total floor area of 6,227㎡ (about 1,886 pyeong) and is designed to be produced and operated on a high quality basis, such as installing a filling line from Germany’s Bausch, which can produce 5.4 million vials of botulinum toxin per year.

Protox, which started exporting after obtaining permission for export of Protoxin stocks last year, plans to make full-fledged sales from this year.

Reporter Choo Min-sun cms@newsprime.co.kr